Log in lub Create an account.
Journal of the Polish Society of Internal Medicine founded by professor Władysław Antoni Gluziński
Indexed in:
MEDLINE/Index Medicus,
EMBASE/Excerpta Medica Database,
Index Copernicus (IC), KBN/MNiSW,
Polish Medical Library (GBL), EBSCO,
ISI Science Citation Index Expanded,
Scopus,
Directory of Open Access Journals (DOAJ)
IC Value for 2009: 7.80 pts,
MNiSW Value: 9 pts.
The journal receives funding from the Ministry of Science and Higher Education for promoting scientific research.
Polish Archives of Internal Medicine is an open-access journal and does not charge readers for access to the full texts of the articles.
Partner Polskiej Interny
Ewa Stępień, Konstanty Szułdrzyński, Agnieszka Branicka, Elżbieta Stankiewicz, Agnieszka Pazdan, Łukasz Zieliński, Maria Bożek, Marek Tomala, Bartłomiej Guzik, Jacek Godlewski, Tomasz Pawelec, Krzysztof Żmudka
Abstract
Introduction. The PlA2 allele is present in about 20–30% of European population. This allele has been
associated with resistance to the antithrombotic action of aspirin in healthy PlA2 carriers. Objectives. To evaluate
the functional association of the PlA1/A2 polymorphism of β3 intergrins with increased thrombin generation and
platelet activation in patients with coronary artery disease (CAD), treated with low-dose aspirin and whether the
effect of this polymorphism is modulated by statin administration. Patients and methods. In 31 patients (25 M,
6 F) with CAD, aged 47 to 76 years, the thrombin-antithrombin complex generation (TAT) and the soluble form
of CD40 ligand level (sCD40L) in blood collected every 60 seconds at sites of standardized microvascular injury
were determined. Results. Coronary angiography revealed ≥1 major epicardial artery stenosis (≥50%) in all patients. Genotyping determined 18 subjects homozygous for PlA1 and 13 PlA2 heterozygous carriers.
Homozygous PlA1 subjects exhibited increased fibrinogen levels compared with PlA2 carriers (4.2 [IQ 2.39] g/l
vs. 2.5 [0.73] g/l, p <0.05). Maximal TAT level observed 6 min after microvascular injury was higher in PlA2
carriers (p = 0.01). Maximal sCD40L did not differ between PlA1/A1 subjects and PlA2 carriers. The PlA2 allele
did not alter the velocity of TAT production and sCD40L release. The analysis of the area under the concentration
vs. time curve for TAT revealed that PlA2 carriers exhibited increased thrombin generation compared with
PlA1A1 subjects (by 17.5%, p <0.05). Subjects treated with statins (n = 12) had lower TAT generation and
sCD40L release than non-treated (by 20%, p <0.005 and 23%, p <0.005, respectively). This effect was not
altered by the PlA2 presence. Conclusions. In a model of microvascular injury the PlA1/A2 polymorphism
influenced thrombin formation but not platelet activation in CAD patients treated with low-dose aspirin. The PlA2
allele did not alter the beneficial effect of statins on blood coagulation.
Keywords
PlA1/A2 polymorphism, platelet activation, statins, thrombin generation
Pol Arch Med Wewn, 2007; 117 (1-2): 33-40
PMID: 17642204